Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients

International Journal of Clinical Practice

Volumn 59, Issue 9, 2005, Pages 1001-1004

  Durmus, A ^a   Dogan, Ekrem ^b   Erkoc, R ^b   Sayarlioglu, H ^b   Topal, C ^c   Dilek, I ^b  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b YUZUNCU YIL UNIVERSITY   (Turkey)

^c Trabzon State Hospital   (Turkey)

Author keywords

Angiotensin II AT1 receptor blockers; ARB; CKD; Erythropoietin; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; ERYTHROPOIETIN; FUROSEMIDE; HEMOGLOBIN; NITROGEN; POTASSIUM; UREA; URIC ACID; VALSARTAN; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STUDENT T TEST; UREA NITROGEN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD UREA NITROGEN; CREATININE; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POTASSIUM; TETRAZOLES; URIC ACID; VALINE;

EID: 33644847502     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00606.x     Document Type: Article

References (25)

1. Kushner D, Beckman B, Nguyen L et al. Polyamines in the anemia of end-stage renal disease. Kidney Int 1991; 39: 725-32.
2. Ruggenenti P. Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 2004; 24: 158-67.
3. Freudenthaler SM, Schreeb K, Korner T, Gleiter CH. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 1999; 29: 816-23.
4. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37 (Suppl. 1): 182-238,.
5. Gossmann J, Thürmann P, Bachmann T et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50: 973-8.
6. Danovitch GM, Jamgotchian NJ, Eggena PH et al. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Transplantation 1995; 60: 132-7.
7. Gould AB, Goodman S, Dewolf R, Onesti G, Swartz C. Interrelation of the rennin system and erythropoietin in rats. J Lab Clin Med 1980; 96: 523-34.
8. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-10.
9. Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting "enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 1995; 10: 2107-9.
10. Jackson TR, Blair LAC, Marshall J, Goedert M, Hanley MR. The mas oncogene encodes an angiotensin receptor. Nature 1988; 335: 437-40.
11. Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 1989; 13 (Suppl. 3): S27-30.
12. Perazella M, Kliger A, Levy E, McPhedran P, Lorber M, Bia MJ. Enalapril treatment of posttransplant erythrocytosis: Mechanism of action. J Am Soc Nephrol 1993; 4: 954.
13. Erturk S, Nergizoglu G, Ates K, et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1836-41.
14. Shand BI, Bailey RR, Lynn KL, Robson RA. Effect of Enalapril on Erythrocytosis in Hypertensive Patients with Renal Disease. Blood Press 1995; 4: 238-40.
15. Hess E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? (letter). Nephrol Dial Transplant 1997; 11: 749.
16. Walter J. Does catopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? (letter). Nephrol Dial Transplant 1993; 8: 142.
17. Pratt MC, Lewis-Barned NJ, Walker RJ, Bailey RR, Shand BI, Livesey J. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 1992; 34: 363-5.
18. Abu-Alfa AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis. Am J Kidney Dis 2000; 35: 1076-82.
19. Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis: any evidence of erythropoietin resistance. Am J Kidney Dis 1996; 28: 535.
20. Sanchez JA. ACE inhibitors do not decrease rHuEPO response in patients with end-stage renal failure (letter). Nephrol Dial Transplant 1995; 10: 1476.
21. Conlon PJ, Albers F, Butterly D, Schwab S. ACE inhibitors do not affect erythropoeitin efficiency in hemodialysis patients (letter). Nephrol Dial Transplant 1994; 9: 1359.
22. Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol 2003; 23: 287-93.
23. Chew CG. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of hemodialysis patients (letter). Nephrol Dial Transplant 1999; 14: 2047.
24. Shand BI, Gilchrist NL, Nicholls MG, Bailey RR. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: A pilot study. J Hum Hypertens 1995; 9: 233-5.
25. Robles NR, Angulo E, Grois J, Barquero A. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren Fail 2004; 26: 399-404.